Advertise
NEWSLETTER
European consortium creates...
Avaí Bio, Austrianova, Ospe...
Restore, Niagen Bioscience ...
Experimental eye treatment ...
Jupiter Neurosciences doses...
European consortium creates...
Avaí Bio, Austrianova, Ospe...
Restore, Niagen Bioscience ...
Experimental eye treatment ...
Jupiter Neurosciences doses...
ChromaDex

Niagen launches telehealth NAD+ injection platform

Niagen Bioscience secures patent for NR injections

NAD+ pioneer debuts new beauty supplement

Defined as coronavirus symptoms that last longer than four weeks after initial infection, it can cause continued breathing difficulties, brain fog, weakness and fatigue as well as other neurological issues.

NAD+ boost shows promise in Long COVID study

FDA reverses NMN decision

Chromadex CEO Rob Fried on NAD+, longevity, and the next frontier in cellular health

Dr Alyssa Dweck explains why ChromaDex’s latest NAD-boosting supplement is optimised to combat the impact of immune stress.

A clinician’s view: We need to manage immune stress better

Niagen Bioscience secures exclusive rights for Parkinson’s therapy

Lab tests raise concerns over longevity supplements label accuracy

Lab tests raise concerns over longevity supplements label accuracy

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE

  • $617BN - Annual global revenue by 2045
  • $30BN+ - Invested in under 2 years
  • 3,036 - Therapeutics individually assessed